Portage Biotech Announces Financial Results and Provides Business Update for Third Quarter of 2022 Fiscal Year

$PRTG
Oil & Gas Production
Energy
Get the next $PRTG alert in real time by email

WESTPORT, Conn., Feb. 24, 2022 (GLOBE NEWSWIRE) -- Portage Biotech Inc. (NASDAQ:PRTG) ("Portage" or the "Company"), a clinical-stage immuno-oncology company developing therapies to improve patient lives and increase survival by avoiding and overcoming cancer treatment resistance, today announced financial results for the quarter ended December 31, 2021 (the "third quarter").

"During the third quarter and in recent weeks we've taken steps to accelerate our lead programs for PORT-2 and PORT-3, investigating options to expand our clinical sites beyond our current footprint and finding the means of accelerating patient enrollment," said Dr. Ian Walters, chief executive officer of Portage. "With our enhanced management team, efficient organization, and financial resources obtained in 2021, we are well positioned to execute our unique drug development strategy to deliver on important clinical milestones over the next two years."

Business Update

  • Enhanced the management team with the appointments of Brian Wiley as Chief Business Officer, Joseph Ciavarella as Chief Accounting Officer; expanded the Board of Directors with the addition of Jim Mellon, Linda Kozick, and Mark Simon.
  • Enrollment continues in the Company's IMP-MEL randomized Phase 1/2 study of PORT-2 and its PRECIOUS Phase 1 study of PORT-3 in patients with NY-ESO-1 expressing tumors.
  • The Company plans to issue a Research & Development update in March 2022 which will include preliminary safety data on its PORT-2 and PORT-3 programs as well as other details from its clinical development plan.
  • Presented at high-profile investor conferences:
    • Management participated in January 2022 investor conferences including the LifeSci Advisors Corporate Access Event, H.C. Wainwright BioConnect Conference, and the B. Riley Securities' Oncology Investor Conference.
  • Hosted Key Opinion Webinar How iNKT Agonists Could Improve Immuno-Oncology Treatment with leading researchers from La Jolla Institute of Immunology and Imperial College London. Replay available here.

Third Quarter FY 2022 Financial Results

The Company generated a net loss and comprehensive loss of approximately $4.2 million in the three months ended December 31, 2021 ("Fiscal 2022 Quarter"), compared to a net loss and comprehensive loss of approximately $1.3 million in the three months ended December 31, 2020 ("Fiscal 2021 Quarter"), an increase in loss of $2.9 million year over year. Operating expenses, which include research and development and general and administrative expenses, were approximately $4.2 million in the Fiscal 2022 Quarter, compared to $0.9 million in the Fiscal 2021 Quarter, an increase of $3.3 million, which is discussed more fully below.

The Company's other items of income and expense were substantially non-cash in nature and were approximately $0.1 million net income in the Fiscal 2022 Quarter, compared to approximately $0.5 million net loss in the Fiscal 2021 Quarter, a change in other items of income and expense of approximately $0.6 million, year over year. The primary reasons for the year over year difference in other items of income and expense was the change of $0.8 million in the fair value of the warrants issued with respect to the SalvaRx note settlement, which was partially offset by the year over year increase in the loss from an associate accounted for under the equity method of $0.1 million and the income on equity issued at a discount of $0.1 million in the Fiscal 2021 Quarter, representing the difference between the market price and the contractual exercise price, relating to the settlement of the SalvaRx notes and warrants.

Research & development ("R&D") costs increased by approximately $1.5 million, from approximately $0.4 million during the Fiscal 2021 Quarter, to approximately $1.9 million during the Fiscal 2022 Quarter. The increase was primarily attributable to non-cash share-based compensation expense associated with grants made under the 2021 Equity Incentive Plan of $1.0 million and salaries and bonuses of $0.7 million to directors and senior management. Additionally, the Fiscal 2021 Quarter was impacted by a general slow down in expenditures resulting from the pandemic.

General and administrative ("G&A") expenses increased by approximately $1.8 million, from approximately $0.4 million during the Fiscal 2021 Quarter, to approximately $2.2 million during the Fiscal 2022 Quarter. The principal reason for the increase in the Fiscal 2022 Quarter was the $1.1 million of non-cash share-based compensation expense associated with the Company's 2021 Equity Incentive Plan, of which $0.7 million is associated with Directors' compensation, and $0.4 million is associated with management compensation. No share-based compensation expense under the 2021 Equity Incentive Plan was incurred during the Fiscal 2021 Quarter. Additionally, the Company incurred an increase of $0.4 million in professional fees relating to initiatives associated with a corporate restructuring and public relations / business development. Finally, D&O insurance premiums increased $0.4 million in the current year period due to market rate increases in the cost of coverage.

Additionally, the Company reflected a net income tax expense of approximately $0.1 million in the Fiscal 2022 Quarter, compared to a net income tax benefit of approximately $0.1 million in the Fiscal 2021 Quarter. The Fiscal 2022 Quarter reflects the change in the foreign currency exchange rate on deferred tax liability settleable in British pounds sterling and the Fiscal 2021 Quarter reflected recoverable research and development tax credits generated in the U.K.

As of December 31, 2021, the Company had cash and cash equivalents of approximately $25.6 million and total current liabilities of approximately $0.6 million (inclusive of approximately $0.2 million warrant liability settleable on a non-cash basis). For the nine months ended December 31, 2021, the Company is reporting a net loss of approximately $10.3 million and cash used in operating activities of approximately $4.5 million. As of January 31, 2022, the Company had approximately $25.1 million of cash on hand to enable achieving important clinical milestones over the next two years.

About Portage Biotech Inc.

Portage is a clinical-stage immuno-oncology company advancing first-in-class therapies that target known checkpoint resistance pathways to improve long-term treatment response and quality of life in patients with evasive cancers. The Company's access to next-generation technologies coupled with a deep understanding of biological mechanisms enables the identification of the most promising clinical therapies and product development strategies that accelerate these medicines through the translational pipeline. Portage's portfolio consists of five diverse platforms, leveraging delivery by intratumorals, nanoparticles, liposomes, aptamers, and virus-like particles. Within these five platforms, Portage has 10 products currently in development with multiple clinical readouts expected over the next 12-24 months. For more information, please visit www.portagebiotech.com, follow us on Twitter at @PortageBiotech or find us on LinkedIn at Portage Biotech Inc.

Forward-Looking Statements

This news release contains statements about the Company's information that are forward-looking in nature and, as a result, are subject to certain risks and uncertainties. Although the Company believes that the expectations reflected in these forward-looking statements are reasonable, undue reliance should not be placed on them as actual results may differ materially from the forward-looking statements. The forward-looking statements contained in this news release are made as of the date hereof, and the Company undertakes no obligation to update publicly or revise any forward-looking statements or information, except as required by law.

FOR MORE INFORMATION, PLEASE CONTACT:

Investor Relations        

Chuck Padala

chuck@lifesciadvisors.com

Media Relations

Gwen Schanker

gschanker@lifescicomms.com

-tables to follow-



PORTAGE BIOTECH INC.

Consolidated Statements of Operations and Comprehensive Income (Loss)

(U.S. Dollars in thousands, except per share amounts)

  Three months ended

December 31,
  Nine months ended

December 31,
 
  2021  2020  2021  2020 
  In 000'$  In 000'$  In 000'$  In 000'$ 
Expenses            
Research and development $1,928  $414  $4,804  $1,658 
General and administrative expenses  2,241   452   6,288   1,349 
Loss from operations  (4,169)  (866)  (11,092)  (3,007)
Change in fair value of warrant liability  342   (500)  726   (441)
Share of (loss) income in associate accounted for using equity method  (261)  (121)  (363)  270 
Income (loss) on equity issued at a discount     77      (1,256)
Gain on sale of marketable equity securities           72 
(Loss) on extinguishment of notes payable           (223)
Foreign exchange transaction (loss)     (2)     (2)
Interest (expense)  (1)  (3  (42)  (172)
Loss before provision for income taxes  (4,089)  (1,415)  (10,771)  (4,759)
Income tax (expense) benefit  (117)  65   465   65 
Net (loss)  (4,206)  (1,350)  (10,306)  (4,694)
Other comprehensive income (loss)                
Unrealized (loss) on investment            
Total comprehensive (loss) for period $(4,206) $(1,350) $(10,306) $(4,694)
Net (loss) income attributable to:                
Owners of the Company $ (3,512) $(1,184) $(9,553) $(4,335)
Non-controlling interest  (694)  (166)  (753)  (359)
  $(4,206) $(1,350) $(10,306) $(4,694)
Comprehensive (loss) attributable to:                
Owners of the Company $(3,512) $(1,184) $(9,553) $(4,335)
Non-controlling interest  (694)  (166)  (753)  (359)
  $(4,206) $(1,350) $(10,306) $(4,694)
(Loss) per share (Actual)                
Basic and diluted $(0.26) $(0.10) $(0.74) $(0.37)
Weighted average shares outstanding                
Basic and diluted  13,344   12,031   12,966   11,619 

PORTAGE BIOTECH INC.

Consolidated Statements of Financial Position

(U.S. Dollars in thousands)

As of, December 31,

2021
  March 31,

2021
 
     (Audited) 
Assets      
Current assets      
Cash and cash equivalents $25,603  $2,770 
Prepaid expenses and other receivables  672   2,176 
   26,275   4,946 
Long-term assets        
Long-term portion of other receivables     22 
Investment in associate  1,372   1,735 
Investments in private companies  7,409   7,409 
Goodwill  43,324   43,324 
In-process research and development  117,388   117,388 
Other assets  38   36 
Total assets $195,806  $174,860 
         
Liabilities and Equity        
Current liabilities        
Accounts payable and accrued liabilities $477  $1,938 
Warrant liability  159   1,120 
Unsecured notes payable     150 
   636   3,208 
Non-current liabilities        
Deferred tax liability  23,606   24,050 
   23,606   24,050 
Total liabilities  24,242   27,258 
Shareholders' Equity        
Capital stock  158,294   130,649 
Stock option reserve  14,225   7,977 
Accumulated other comprehensive income  958   958 
Accumulated deficit  (47,688)  (38,135)
Total equity attributable to owners of the Company  125,789   101,449 
Non-controlling interest  45,775   46,153 
Total equity  171,564   147,602 
Total liabilities and equity $195,806  $174,860 
Commitments and Contingent Liabilities (Note 17)        


Primary Logo

Get the next $PRTG alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$PRTG

DatePrice TargetRatingAnalyst
7/18/2022$26.00Outperform
Oppenheimer
3/7/2022$32.00Buy
HC Wainwright & Co.
9/21/2021$30.00Outperform
Oppenheimer
9/2/2021$40.00Buy
B. Riley Securities
8/19/2021$35.00Overweight
Cantor Fitzgerald
More analyst ratings

$PRTG
Press Releases

Fastest customizable press release news feed in the world

See more
  • Portage Biotech Reports Promising Preclinical Results in Mesothelioma Supporting First-In-Human Trial of PORT-7

    DOVER, Del., March 27, 2025 (GLOBE NEWSWIRE) -- Portage Biotech Inc. (NASDAQ:PRTG), a clinical-stage immuno-oncology company with a portfolio of innovative therapeutics, presented new preclinical data for PORT-7 (TT-4), a selective Adenosine A2B receptor inhibitor, generated by Dr. Luciano Mutti, Gruppo Italiano Mesotelioma e Oncologia Ambientale, at the 2025 European Lung Cancer Congress (ELCC), held in Paris, France March 26-29. The new data demonstrate both single agent activity for PORT-7, and a dramatic >90% inhibition of tumor growth when PORT-7 was combined with an anti-PD1 antibody in a murine model of mesothelioma. Immunohistochemistry of the tumors revealed a significant infiltra

    $PRTG
    Oil & Gas Production
    Energy
  • Portage Biotech Resumes Enrollment in Final Cohort of Dose Escalation for Port-6 in ADPORT-601 Trial

    DOVER, Del., March 12, 2025 (GLOBE NEWSWIRE) -- Portage Biotech Inc. ("Portage" or the "Company") (NASDAQ:PRTG), a clinical-stage immuno-oncology company with a portfolio of innovative therapeutics, today announced the resumption of patient enrollment in the fourth and final cohort of the dose escalation stage for PORT-6, a highly selective A2A antagonist, within its ADPORT-601 Phase 1b clinical trial. Portage had previously paused this trial due to funding concerns; this resumption of the trial underscores the encouraging findings observed in earlier cohorts. After the completion of the PORT-6 arm of the ADPORT-601 study, Portage will evaluate the continuation of the study into its PORT-7

    $PRTG
    Oil & Gas Production
    Energy
  • Portage Biotech Receives Extension of Time to Attain Compliance With Stock Exchange Continued Listing Requirements

    DOVER, Del., Feb. 12, 2025 (GLOBE NEWSWIRE) -- Portage Biotech, Inc. ("Portage" or the "Company") (NASDAQ:PRTG), a clinical-stage immuno-oncology company with a portfolio of innovative therapeutics, today announced that on February 11, 2025, it received notification from The Nasdaq Stock Market, LLC ("Nasdaq") that Nasdaq has accepted Portage's compliance plan and has granted the Company the extension to regain compliance with the continued listing standards on The Nasdaq Capital Market (the "Capital Market") as set forth in Nasdaq Listing Rule 5550(b)(1) whereby the minimum shareholders' equity is at least $2.5 million or meet either of the alternative continued listing standards for the

    $PRTG
    Oil & Gas Production
    Energy

$PRTG
Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

See more

$PRTG
SEC Filings

See more

$PRTG
Leadership Updates

Live Leadership Updates

See more
  • Portage Biotech Announce Re-Launch of Adenosine Subsidiary as Independently Managed Company; Appointment of Peter Molloy to Lead New Company

    WESTPORT, Conn., Jan. 06, 2025 (GLOBE NEWSWIRE) -- Portage Biotech, Inc. ("Portage" or the "Company") (NASDAQ:PRTG), a clinical-stage immuno-oncology company with a portfolio of innovative therapeutics, today announced the re-launch of its wholly-owned subsidiary as an independently managed company focused on developing best-in-class adenosine receptor antagonists. Peter Molloy has been appointed Chief Executive Officer of the subsidiary, to be named Cyncado TherapeuticsTM, Inc. As CEO, Mr. Molloy will lead efforts to secure external financing directly into Cyncado and to advance the clinical development of its portfolio of A2a and A2b receptor antagonists. These therapeutics are distin

    $PRTG
    Oil & Gas Production
    Energy

$PRTG
Financials

Live finance-specific insights

See more
  • Portage Biotech Acquires Outstanding Minority Interest of Invariant Natural Killer T cell (iNKT) Agonist Platform

    WESTPORT, Conn., July 20, 2022 (GLOBE NEWSWIRE) -- Portage Biotech Inc. (NASDAQ:PRTG), a clinical-stage immuno-oncology company developing therapies to improve patient lives and increase survival by avoiding and overcoming cancer treatment resistance, today announced that the Company has acquired the outstanding ownership interest (approximately 22%) of its invariant natural killer T cell (iNKT agonist) platform and now fully owns the worldwide rights to its small molecule iNKT agonists, including lead programs PORT-2 and PORT-3. The platform was acquired through Portage's iOx Therapeutics Ltd. (iOx) subsidiary from the founding equity holders in exchange for 1,070,000 ordinary shares of P

    $PRTG
    Oil & Gas Production
    Energy
  • Portage Biotech Bolsters Pipeline with Acquisition of Four Candidates Targeting the Adenosine Pathway

    Acquires two clinical-stage, best in class adenosine compounds, and two preclinical assets for approximately $21 million upfront consideration Rob Glassman, M.D., Ph.D., director of Tarus and former Venture partner at OrbiMed, to join the Portage Board of Directors Enters into committed share purchase agreement with Lincoln Park Capital to purchase ordinary shares of Portage for up to $30 Million; proceeds to potentially extend cash runway for current projects into 2024 Management to host a conference call and webcast Thursday, July 7 at 8:30am ET to discuss the adenosine programs and combined pipeline in greater detail WESTPORT, Conn., July 06, 2022 (GLOBE NEWSWIRE) -- Portage

    $PRTG
    Oil & Gas Production
    Energy
  • Portage Biotech Announces Financial Results and Provides Business Update for Third Quarter of 2022 Fiscal Year

    WESTPORT, Conn., Feb. 24, 2022 (GLOBE NEWSWIRE) -- Portage Biotech Inc. (NASDAQ:PRTG) ("Portage" or the "Company"), a clinical-stage immuno-oncology company developing therapies to improve patient lives and increase survival by avoiding and overcoming cancer treatment resistance, today announced financial results for the quarter ended December 31, 2021 (the "third quarter"). "During the third quarter and in recent weeks we've taken steps to accelerate our lead programs for PORT-2 and PORT-3, investigating options to expand our clinical sites beyond our current footprint and finding the means of accelerating patient enrollment," said Dr. Ian Walters, chief executive officer of Portage. "Wi

    $PRTG
    Oil & Gas Production
    Energy

$PRTG
Large Ownership Changes

This live feed shows all institutional transactions in real time.

See more